en
Scientific article
French

Nouveaux traitements systémiques dans le cancer du pancréas avancé : implications sur la survie et considérations médicoéconomiques

Published inRevue médicale suisse, vol. 1, no. 24, p. 1616-1620
Publication date2005
Abstract

More than 75% of patients with advanced pancreas cancer present at a later stage, when only palliative chemotherapy can be offered as the main treatment. Since introduced, gemcitabine has significantly improved the symptomatic impact of the disease, and this single-agent therapy still remains the gold-standard treatment aside of any exploratory protocol. Survival benefits have however been marginal, although a minority of long-term survivors now survives their disease up to two or three years. Results from a retrospective study conducted on cases followed by the oncosurgery service of the Geneva University Hospital from 1993 to 2003 support this observation, and show a trend towards a parallel increase in ambulatory-incurred costs.

Keywords
  • Adult
  • Aged
  • Ambulatory Care/economics
  • Antineoplastic Combined Chemotherapy Protocols/economics/therapeutic use
  • Female
  • Humans
  • Length of Stay/economics/statistics & numerical data
  • Male
  • Middle Aged
  • Pancreatic Neoplasms/drug therapy/mortality
  • Retrospective Studies
  • Switzerland
Citation (ISO format)
MAZZURI, Sebastien, ROTH, Arnaud. Nouveaux traitements systémiques dans le cancer du pancréas avancé : implications sur la survie et considérations médicoéconomiques. In: Revue médicale suisse, 2005, vol. 1, n° 24, p. 1616–1620.
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
ISSN of the journal1660-9379
456views
1downloads

Technical informations

Creation08/18/2014 3:03:00 PM
First validation08/18/2014 3:03:00 PM
Update time03/14/2023 9:31:48 PM
Status update03/14/2023 9:31:47 PM
Last indexation01/16/2024 11:37:23 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack